Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nuvation Bio Inc (NY: NUVB ) 2.490 +0.060 (+2.47%) Official Closing Price Updated: 7:00 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Nuvation Bio Inc < Previous 1 2 Next > Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer October 07, 2024 From Nuvation Bio Inc. Via Business Wire Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 September 14, 2024 From Nuvation Bio Inc. Via Business Wire Nuvation Bio to Present at the Cantor Global Healthcare Conference September 09, 2024 From Nuvation Bio Via Business Wire Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update August 05, 2024 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib July 23, 2024 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting June 01, 2024 From Nuvation Bio Inc. Via Business Wire Nuvation Bio to Present at the Jefferies Global Healthcare Conference May 29, 2024 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update May 14, 2024 From Nuvation Bio Inc. Via Business Wire Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting April 24, 2024 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Completes Acquisition of AnHeart Therapeutics April 10, 2024 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer March 28, 2024 From Nuvation Bio Inc. Via Business Wire Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction March 25, 2024 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors March 14, 2024 From Nuvation Bio Inc. Via Business Wire Biotech’s Role in Addressing the Pancreatic Cancer Emergency March 14, 2024 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END Via FinancialNewsMedia Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update February 29, 2024 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors January 08, 2024 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors January 08, 2024 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Announces Departure of Chief Financial Officer November 13, 2023 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update November 02, 2023 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update August 03, 2023 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board June 01, 2023 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update May 04, 2023 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update March 15, 2023 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868 December 19, 2022 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update November 03, 2022 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update August 04, 2022 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program August 01, 2022 From Nuvation Bio Inc. Via Business Wire Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer July 18, 2022 From Nuvation Bio Inc. Via Business Wire INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm June 30, 2022 From The Schall Law Firm Via Business Wire INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm June 29, 2022 From The Schall Law Firm Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.